Praxis Precision Medicines (PRAX) EV/EBIT: History & Chart

Praxis Precision Medicines, Inc.(PRAX)

Biotechnology · Boston, MA

$280.39-3.17 (-1.12%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.

Boston, MA

168 employees

www.praxismedicines.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Marcio Silva De'Souza

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Praxis Precision Medicines, Inc. (PRAX)	$7.82B	N/A	N/A	N/A	N/A
Caris Life Sciences, Inc. (CAI)vs ›	$7.76B	49.08x	45.18x	45.18x	45.18x
TG Therapeutics, Inc. (TGTX)vs ›	$7.99B	60.60x	53.63x	69.89x	69.89x
Cytokinetics, Incorporated (CYTK)vs ›	$7.63B	N/A	260.19x	260.19x	260.19x
HealthEquity, Inc. (HQY)vs ›	$7.61B	23.87x	26.07x	43.43x	99.57x
Hinge Health, Inc. (HNGE)vs ›	$7.61B	78.20x	77.57x	176.68x	176.68x
Ionis Pharmaceuticals, Inc. (IONS)vs ›	$7.31B	N/A	860.73x	332.81x	269.88x
Oscar Health, Inc. (OSCR)vs ›	$8.38B	7.60x	269.89x	133.90x	133.90x
Alkermes plc (ALKS)vs ›	$6.99B	68.62x	33.08x	18.53x	18.91x
Arrowhead Pharmaceuticals, Inc. (ARWR)vs ›	$8.67B	N/A	57.60x	57.60x	57.60x

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Praxis Precision Medicines, Inc. (PRAX)

$7.82B

N/A

Caris Life Sciences, Inc. (CAI)vs ›

$7.76B

49.08x

45.18x

TG Therapeutics, Inc. (TGTX)vs ›